STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy
CHICAGO — Lipoprotein(a), a genetic risk factor for cardiovascular disease carried by 1 in 5 people, is the target of novel therapies trying to cut down heart attacks, strokes, and deaths in those at risk.
Key points
- The growing field of research aimed at the particle took a hit earlier this year when top-line results showed an experimental drug reduced Lp(a) but failed to lower serious outcomes.
- In the Phase 3 trial, the drug pelacarsen dramatically lowered Lp(a), a mashup of lipids and proteins that at high levels can heighten the risk of severe heart problems.
But despite lower Lp(a), the HORIZON trial showed no difference in heart attacks, strokes, urgent coronary revascularization, or deaths in participants followed for almost five years who were randomly selected to take the drug or a placebo.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.